hotspot -WSS

hotspot

author：knowledge 2025-09-27 23:53:42 - browse：3236

Dallas Mavericks owner Mark Cuban reacts during a timeout in the game against the Golden State Warriors at American Airlines Center on March 22, 2023 in Dallas, Texas. – opinion coverage from STAT — Tim Heitman/Getty Images

Mark Cuban, the Dallas Mavericks owner and “Shark Tank” star, has been making headlines recently with his direct-to-consumer venture, Cost Plus Drugs. The company sells generic prescription drugs and boasts more than 2 million members. As a family medicine specialist who has firsthand experience with American households’ dissatisfaction with the state of the nation’s prescription drug marketplace, I believe the enthusiasm for Cost Plus Drugs reveals an appetite for alternatives to the status quo in the pharmaceutical industry.

Cuban claims the reason behind the success of Cost Plus Drugs is the company’s decision to bypass pharmaceutical benefit managers — the negotiating agents insurance companies hire to negotiate big pharma’s prices down. But that might not be the case. Instead, its success appears to lie in its choice to collaborate with affordable generic drug manufacturers rather than the major pharmaceutical companies.

Last year, the Department of Health and Human Services found that between July 2021 and July 2022, major pharma companies raised the list price on more than 1,200 drugs by an average of 31 percent. That’s 23 percent more than the country’s overall inflation rate during the same period. Meanwhile, generic drug companies saved the U.S. roughly $2.6 trillion from 2012 to 2021, according to the Association for Accessible Medicines, a trade group representing generic drug manufacturers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

focus

WSS

Steward Health Care Massachusetts hospitals face fiscal disaster

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

How many hemophilia patients actually want gene therapy?

FTC falls short on scrutinizing hospital mergers, study says

Q&A: Jennifer Adair on making gene therapy available globally

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

focus

hotspot

focus

Affirmative action in medical school literally saved lives

First U.S. drug developed to treat liver disease MASH is approved

Tori Bowie and the unacceptable rates of Black maternal death

WuXi out of biotech trade group, U.S. and China relations to blame

Drug repurposing or repositioning? The language matters

Readout Newsletter: CAR

DIEP, the 'gold standard' of breast reconstruction, is under threat

EPA limits use of carcinogenic gas for sterilizing medical devices

What does generative AI mean for health care? We asked experts

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

explore

Medicare coverage of Wegovy, once blocked, now looks possible

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Close Medicare's dangerous gaps in addiction treatment coverage

Ebola: Gilead Sciences antiviral shows promise as new treatment

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

hotspot

focus

knowledge

entertainment